-
Group
BackGroupView
-
Who we are
BackWho we areView
- Profile
- Key figures
-
Governance
BackGovernanceView
-
Governance
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Our history
-
Who we are
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
What we do
BackWhat we doView
- At a glance
- Large Industries
- Industrial Merchant
- Healthcare
- Electronics
- Engineering & Construction
- Global Markets & Technologies
-
What we do
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Our strategy
BackOur strategyView
-
Our strategy
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Innovation
BackInnovationView
-
Research & Development
BackResearch & DevelopmentView
-
Research & Development
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Digital transformation
-
Global markets & Technologies
BackGlobal markets & TechnologiesView
-
Global markets & Technologies
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Air Liquide Venture Capital
-
Innovation
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Research & Development
-
Sustainable development
BackSustainable developmentView
- Safety
-
Ethics
BackEthicsView
-
Ethics
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Human rights
- Climate objectives
- Environmental data
- Vigilance plan
- Extra-financial ratings
-
Stakeholders
BackStakeholdersView
-
Stakeholders
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Sustainable development
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
- Where we operate
- Group publications
-
Group
- Quick Access
- Executive Committee
- 2019 Annual Report
- Air Liquide Foundation website
-
Who we are
-
Businesses
BackBusinessesView
-
Industry
BackIndustryView
-
Industry
-
Healthcare
BackHealthcareView
- Presentation
-
Our expertise
-
Our R&D
- Diseases
-
Public health challenges
BackPublic health challengesView
- Aging population
- Rise in chronic diseases
- Urbanization and lifestyle changes
- Reinventing the hospital
-
Public health challenges
-
Healthcare
-
Electronics
-
Engineering & Construction
BackEngineering & ConstructionView
-
Engineering & Construction
-
Science & New energies
BackScience & New energiesView
-
Science & New energies
-
Businesses
-
Industry
-
Magazine
BackMagazineView
- Industry of the future
- Healthcare
- Energy transition
- Customer experience
- Digitization
- Open innovation
- Science
-
Magazine
- Customers
-
Shareholders
BackShareholdersView
- Stock & Share: shareholders' mag
- Become a shareholder
-
Follow the Air Liquide share
BackFollow the Air Liquide shareView
-
Follow the Air Liquide share
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
-
Factsheets
BackFactsheetsView
- Understanding the stock market
- Stock orders
- Shareholding options
- Registering shares
- Loyalty bonus
- Personal online Account
- Capital gains
- Free share attribution
- Dividend
- Taxation
- Passing on shares
-
Factsheets
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
- Shareholders' Communication Committee
- Annual General Meeting
- Agenda
-
Media library
BackMedia libraryView
-
Media library
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
- Contact us
-
Shareholders
- Access your Account
- Open a share Account
- Quick Access
- 2020 Annual General Meeting
- Forms
- Contact us
-
Investors
BackInvestorsView
- Agenda
- Documents & Presentations
- Vara consensus
-
Investing in Air Liquide
BackInvesting in Air LiquideView
-
Investing in Air Liquide
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Credit investor
BackCredit investorView
-
Credit investor
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Governance
BackGovernanceView
- Corporate officers remuneration and regulated commitments
- Board committees
- Capital and articles of association, Internal Regulations, disclosure of share buy-back transactions
-
Governance
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
- Regulated information
- Contact us
-
Investors
- Quick Access
- First Half 2020 Results
- 2019 Universal Registration Document
- Group's latest press releases
-
Media
-
Careers
BackCareersView
- Job offers
- I choose Air Liquide
-
Careers at Air Liquide
BackCareers at Air LiquideView
-
Careers at Air Liquide
- Find our job offers
- Spontaneous application
-
You at Air Liquide
BackYou at Air LiquideView
-
You at Air Liquide
- Find our job offers
- Spontaneous application
- Students
-
Graduates
BackGraduatesView
-
Graduates
- Find our job offers
- Spontaneous application
Covid-19: Air Liquide is mobilized to increase its production of CryopAL medical oxygen vessels for home healthcare and long-term care facilities
CryopAL, a subsidiary of Air Liquide, handles the manufacturing of the Freelox line of liquid oxygen vessels for medical use. These vessels are primarily used in home healthcare or long-term care facility settings to supply oxygen to patients suffering from respiratory insufficiency. In response to the Covid-19 outbreak, the company has tripled its production capacity and is preparing to further increase it to meet the needs of the growing number of patients who receive home healthcare services, and to equip facilities that do not have an existing piped oxygen network.
In the context of the evolving Covid-19 pandemic in Europe, CryopAL has mobilized its resources to increase production capacity for its Freelox vessels, which store and release medical liquid oxygen. These vessels, which can hold 32 or 44 liters of liquid oxygen, enable patients to self-monitor their own treatment for about a week[1]. Fabricated at its plant in Bussy-Saint-Georges, near Paris (77), the usual production capacity is around 100 vessels a week. Currently, capacity has been increased to 300 vessels a week. In addition, CryopAL stands ready to significantly increase its production further, if necessary, by concentrating its competencies on this activity.
CryopAL supplies home healthcare providers, who then deliver full vessels (or refill them onsite) to patients in their homes or in non-hospital care settings. Given the exceptional situation that hospitals are currently facing, numerous patients who do not have Covid-19 but who require respiratory assistance are being cared for at home thanks to Freelox oxygen vessels. In addition, nursing homes and other care facilities that don’t have a piped oxygen network are turning to CryopAL in order to procure oxygen and supply it to their patients. Lastly, this solution could also benefit patients with Covid-19 who are well enough to leave the hospital but who still require oxygen.
Emilie Mouren-Renouard, Member of the Air Liquide Executive Committee in charge of Innovation, Digital & IT, Intellectual Property, and Global Markets & Technologies WBU, commented:
“As we face the exceptional challenge of fighting Covid-19, the teams at CryopAL are proud to leverage their expertise in the design and manufacturing of equipment to support a growing number of patients who need oxygen therapy at home. This contribution, illustrating our teams’ solidarity, comes in addition to other initiatives undertaken by the Group to fight against Covid-19.”
- ^ The standalone capacity of vessels depends on the oxygen flow used by patients on the basis of their condition and the prescription delivered by their physician.
For more than 50 years, CryopAL has been designing, manufacturing and selling cryogenic vessels for the cryopreservation of biological samples and the treatment of respiratory diseases at home by liquid oxygen therapy. CryopAL employs 85 people in France.
© Air Liquide 2019